Zinc finger protein 469 (ZNF469)
Homo sapiens — UniProt Q96JG9
Gene: ZNF469Homo sapiensSwissProt reviewed
Data last refreshed: (UniProt release unknown)
Key facts
Zinc finger protein 469 (ZNF469) is a protein from Homo sapiens identified by UniProt accession Q96JG9, 3953 residues long. MolForge cross-references it against 0 known binders and 101 disease associations.
- UniProt accession: Q96JG9; gene symbol ZNF469.
- Organism: Homo sapiens.
- Length: 3953 amino acids.
- Top disease associations (Open Targets): brittle cornea syndrome, keratoconus 1 and Abnormality of the cardiovascular system.
- 3D structure: AlphaFold model available.
Target properties
| Protein name | Zinc finger protein 469 |
|---|---|
| UniProt accession | Q96JG9 |
| Gene | ZNF469 |
| Organism | Homo sapiens |
| Length | 3953 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | — |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|---|
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (101)
Diseases linked to this target (Open Targets).
- brittle cornea syndrome · score 0.74
- keratoconus 1 · score 0.53
- Abnormality of the cardiovascular system · score 0.53
- lean body mass · score 0.42
- appendicular lean mass · score 0.40
- Ehlers-Danlos syndrome · score 0.40
- central corneal thickness · score 0.40
- fat body mass · score 0.36
- sitting height measurement · score 0.35
- intraocular pressure measurement · score 0.34
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|---|---|---|---|
| AF-Q96JG9-F2 | alphafold | PREDICTED | 41.35 | — |
| AF-Q96JG9-F13 | alphafold | PREDICTED | 41.17 | — |
| AF-Q96JG9-F14 | alphafold | PREDICTED | 40.86 | — |
| AF-Q96JG9-F12 | alphafold | PREDICTED | 40.83 | — |
| AF-Q96JG9-F11 | alphafold | PREDICTED | 40.80 | — |
| AF-Q96JG9-F3 | alphafold | PREDICTED | 40.62 | — |
| AF-Q96JG9-F4 | alphafold | PREDICTED | 40.60 | — |
| AF-Q96JG9-F5 | alphafold | PREDICTED | 40.08 | — |
Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q96JG9.
Amino-acid sequence (3953 residues)
MPGERPRGAP PPTMTGDLQP RQVASSPGHP SQPPLEDNTP ATRTTKGARE AGGQAQAMEL PEAQPRQARD GELKPPSLRG QAPSSTPGKR GSPQTPPGRS PLQAPSRLAG RAEGSPPQRY ILGIASSRTK PTLDETPENP QLEAAQLPEV DTPQGPGTGA PLRPGLPRTE AQPAAEELGF HRCFQEPPSS FTSTNYTSPS ATPRPPAPGP PQSRGTSPLQ PGSYPEYQAS GADSWPPAAE NSFPGANFGV PPAEPEPIPK GSRPGGSPRG VSFQFPFPAL HGASTKPFPA DVAGHAFTNG PLVFAFHQPQ GAWPEEAVGT GPAYPLPTQP APSPLPCYQG QPGGLNRHSD LSGALSSPGA AHSAPRPFSD SLHKSLTKIL PERPPSAQDG LGSTRGPPSS LPQRHFPGQA YRASGVDTSP GPPDTELAAP GPPPARLPQL WDPTAAPYPT PPGGPLAATR SMFFNGQPSP GQRLCLPQSA PLPWPQVLPT ARPSPHGMEM LSRLPFPAGG PEWQGGSQGA LGTAGKTPGP REKLPAVRSS QGGSPALFTY NGMTDPGAQP LFFGVAQPQV SPHGTPSLPP PRVVGASPSE SPLPSPATNT AGSTCSSLSP MSSSPANPSS EESQLPGPLG PSAFFHPPTH PQETGSPFPS PEPPHSLPTH YQPEPAKAFP FPADGLGAEG AFQCLEETPF PHEGPEVGRG GLQGFPRAPP PYPTHHFSLS SASLDQLDVL LTCRQCDRNY SSLAAFLAHR QFCGLLLARA KDGHQRSPGP PGLPSPPAAP RVPADAHAGL LSHAKTFLLA GDAQAEGKDD PLRTGFLPSL AATPFPLPAS DLDMEDDAKL DSLITEALNG MEYQSDNPEI DSSFIDVFAD EEPSGPRGPS SGHPLKSKAG VTPESKAPPP LPAATPDPQT PRPGDRGCPA RGRPKTRSLG LAPTEADAPS QGRQQRRGKQ LKLFRKDLDS GGAAEGSGSG GGGRASGLRP RRNDGLGERP PPRPRRPRTQ APGSRADPAP RVPRAAALPE ETRSSRRRRL PPRKDPRKRK ARGGAWGKEL ILKIVQQKNR RHRRLGRRAG RCGSLAAGRP RPGAEDRRLR EYDFASESEE DEQPPPRGPG FRGRRGRGEK RKEVELTQGP REDEPQKPRK AARQEAGGDG APANPEEPGG SRPGPGRSPQ ARGPSRSLET GAAAREGGPK CADRPSVAPK DPLQVPTNTE TSEETRPSLD FPQEAKEPET AEESAPDSTE FTEALRSPPA ACAGEMGASP GLLIPEQPPP SRHDTGTPKP SGSLANTAPH GSSPTPGVGS LLGGPGGTQA PVSHNSKDPP ARQPGEFLAP VANPSSTACP KPSVLSSKIS SFGCDPAGFN RDPLGVPVAK KGPQPYSSPH SELFLGPKDL AGCFLEELHP KPSARDAPPA SSSCLCQDGE DAGSLEPQLP RSPPGTAETE PGRAASPPTL ESSSLFPDLP VDRFDPPLYG SLSANRDSGL PFACADPPQK TVPSDPPYPS FLLLEEVSPM LPSHFPDLSG GKVLSKTCPP ERTVVPGAAP SLPGKGSGCS VALMSHLSED ELEIQKLVTE LESQLQRSKD TRGAPRELAE AESVGRVELG TGTEPPSQRR TCQATVPHED TFSAADLTRV GESTAHREGA ESAVATVEAV QGRPGGTWPC PASFHPGHAA LLPCAQEDLV SGAPFSPRGA NFHFQPVQKA GASKTGLCQA EGDSRPPQDV CLPEPSKQPG PQLDAGSLAK CSPDQELSFP KNKEAASSQE SEDSLRLLPC EQRGGFLPEP GTADQPHRGA PAPEAFGSPA VHLAPDLAFQ GDGAPPLDAT WPFGASPSHA AQGHSAGRAG GHLHPTAGRP GFEGNEFAPA GASSLTAPRG REAWLVPVPS PACVSNTHPS RRSQDPALSP PIRQLQLPGP GVAKSKDGIL GLQELTPAAQ SPPRVNPSGL EGGTVEGGKV ACGPAQGSPG GVQVTTLPAV AGHQLGLEAD GHWGLLGQAE KTQGQGTANQ LQPENGVSPG GTDNHASVNA SPKTALTGPT EGAVLLEKCK GSRAAMSLQE EAEPTPSPPS PNRESLALAL TAAHSRSGSE GRTPERASSP GLNKPLLATG DSPAPSVGDL AACAPSPTSA AHMPCSLGPL PREDPLTSPS RAQGGLGGQL PASPSCRDPP GPQQLLACSP AWAPLEEADG VQATTDTGAE DSPVAPPSLT TSPCDPKEAL AGCLLQGEGS PLEDPSSWPP GSVSAVTCTH SGDTPKDSTL RIPEDSRKEK LWESPGRATS PPLAGAVSPS VAVRATGLSS TPTGDEAQAG RGLPGPDPQS RGAPPHTNPD RMPRGHSSYS PSNTARLGHR EGQAVTAVPT EPPTLQGAGP DSPACLEGEM GTSSKEPEDP GTPETGRSGA TKMPRVTCPS TGLGLGRTTA PSSTASDFQS DSPQSHRNAS HQTPQGDPLG PQDLKQRSRG YKKKPASTEN GQWKGQAPHG PVTCEVCAAS FRSGPGLSRH KARKHRPHPG APAEPSPAAL PAQQPLEPLA QKCQPPRKKS HRVSGKERPN HSRGDPSHVT QPPPAQGSKE VLRAPGSPHS QQLHPPSPTE HEVDVKTPAS KPRPDQARED ELHPKQAEKR EGRRWRREPT VDSPSHSEGK SNKKRGKLRG RRLREESILP VSADVISDGR GSRPSPAMAS YAASPSHCLS VEGGPEADGE QPPRLATLGP GVMEGAAETD QEALCAGETG AQKPPGDRML CPGRMDGAAL GEQPTGQKGA SARGFWGPRE TKALGVCKES GSEPAEDSSR AHSRSEEGVW EENTPPLGPL GFPETSSSPA DSTTSSCLQG LPDNPDTQGG VQGPEGPTPD ASGSSAKDPP SLFDDEVSFS QLFPPGGRLT RKRNPHVYGK RCEKPVLPLP TQPSFEEGGD PTLGPARLPT DLSDSSSLCL CHEDPWEDED PAGLPESFLL DGFLNSRVPG IDPWAPGLSL WALEPSREAG AEKLPSHCPE DDRPEAIPEL HMVPAAWRGL EMPAPADDSS SSLGDVSPEP PSLERERCDG GLPGNTHLLP LRATDFEVLS TKFEMQDLCF LGPFEDPVGL PGPSFLDFEG TASSQGPQSR RTEEAAGAGR AQGRGRPAKG RRASYKCKVC FQRFRSLGEL DLHKLAHTPA PPPTCYMCVE RRFGSRELLR GHLQERHAQS KAGPWACGMC LKEVADVWMY NEHLREHAVR FARRGQARRS LGDLPGGLEG SSAVAHLLNS ITEPAPKHHR GKRSAGKAAG SPGDPWGQEG EAKKDSPGER AKPRARSTPS NPDGAATPDS ASATALADAG SPGPPRTTPS PSPDPWAGGE PLLQATPVHE ACKDPSRDCH HCGKRFPKPF KLQRHLAVHS PQRVYLCPRC PRVYPEHGEL LAHLGGAHGL LERPELQHTP LYACELCATV MRIIKKSFAC SSCNYTFAKK EQFDRHMNKH LRGGRQPFAF RGVRRPGAPG QKARALEGTL PSKRRRVAMP GSAPGPGEDR PPPRGSSPIL SEGSLPALLH LCSEVAPSTT KGWPETLERP VDPVTHPIRG CELPSNHQEC PPPSLSPFPA ALADGRGDCA LDGALERPEN EASPGSPGPL LQQALPLGAS LPRPGARGQD AEGKRAPLVF SGKRRAPGAR GRCAPDHFQE DHLLQKEKEV SSSHMVSEGG PRGAFHKGSA TKPAGCQSSS KDRSAASTPS KALKFPVHPR KAVGSLAPGE LARGTENGMK PATPKAKPGP SSQGSGSPRP GTKTGGGSQP QPASGQLQSE TATTPAKPSF PSRSPAPERL PARAQAKSCT KGPREAGEQG PHGSLGPKEK GESSTKRKKG QVPGPARSES VGSFGRAPSA PDKPPRTPRK QATPSRVLPT KPKPNSQNKP RPPPSEQRKA EPGHTQRKDR LGKAFPQGRP LLRPPKRGTA VHGAEPAEPH THRTAEAQSD LLSQLFGQRL TGFKIPLKKD ASE
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
Which diseases are associated with ZNF469?
The strongest Open Targets associations for ZNF469 are brittle cornea syndrome, keratoconus 1, Abnormality of the cardiovascular system, lean body mass and appendicular lean mass.
How long is the ZNF469 protein?
The Homo sapiens ZNF469 protein (UniProt Q96JG9) is 3953 amino acids long.
Browse: Targets: Z · all protein targets A–Z · drugs A–Z.
Sources
- UniProtKB Q96JG9 — name, gene, function, sequence, keywords (CC BY 4.0)
- AlphaFold DB Q96JG9 — predicted 3D structure (CC BY 4.0)
- Open Targets Platform — disease associations and tractability (CC0)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.